acut
exacerb
copd
th
ere
consider
recent
interest
caus
mechan
exacerb
chronic
obstruct
pulmonari
diseas
copd
copd
exacerb
import
caus
consider
morbid
mortal
found
copd
copd
exacerb
increas
increas
sever
copd
patient
prone
frequent
exacerb
import
caus
hospit
admiss
readmiss
frequent
exacerb
may
consider
impact
qualiti
life
diseas
progress
mortal
fig
copd
exacerb
also
associ
consider
physiolog
deterior
increas
airway
infl
ammatori
chang
caus
varieti
factor
virus
bacteria
possibl
common
pollut
copd
exacerb
common
winter
month
may
import
interact
cold
temperatur
exacerb
caus
virus
pollut
earlier
descript
copd
exacerb
concentr
mainli
studi
hospit
admiss
though
copd
exacerb
treat
commun
associ
hospit
admiss
cohort
moderatetosever
copd
patient
follow
east
london
uk
east
london
copd
studi
daili
diari
card
peak
fl
ow
read
ask
report
exacerb
soon
possibl
symptomat
onset
th
e
diagnosi
copd
exacerb
base
criteria
modifi
ed
describ
anthonisen
colleagu
requir
two
symptom
diagnosi
one
must
major
symptom
increas
dyspnoea
sputum
volum
sputum
purul
minor
exacerb
symptom
includ
cough
wheez
sore
throat
nasal
discharg
fever
tabl
th
e
studi
found
exacerb
unreport
research
team
despit
consider
encourag
provid
diagnos
diari
card
diff
erenc
major
symptom
physiolog
paramet
report
unreport
exacerb
patient
copd
accustom
frequent
symptom
chang
thu
may
tend
underreport
exacerb
physician
th
ese
patient
high
level
anxieti
depress
may
accept
situat
th
e
tendenc
patient
underreport
exacerb
may
explain
higher
total
rate
exacerb
per
patient
per
year
higher
previous
report
anthonisen
cowork
per
patient
per
year
howev
latter
studi
exacerb
unreport
diagnos
patient
recal
symptom
use
median
number
exacerb
cutoff
point
copd
patient
east
london
studi
classifi
ed
frequent
infrequ
exacerb
qualiti
life
score
measur
use
valid
diseasespecifi
c
scale
st
georg
respiratori
questionnair
sgrq
signifi
cantli
wors
three
compon
score
symptom
activ
impact
frequent
compar
infrequ
exacerb
th
suggest
exacerb
frequenc
import
determin
health
statu
copd
thu
one
import
outcom
measur
copd
factor
predict
frequent
exacerb
includ
daili
cough
sputum
frequent
exacerb
previou
year
previou
cold
longer
recoveri
time
exacerb
symptom
dyspnoea
common
cold
sore
throat
cough
increas
signifi
cantli
prodrom
phase
suggest
respiratori
virus
may
earli
eff
ect
exacerb
th
e
median
time
recoveri
peak
expiratori
fl
ow
day
day
symptom
day
peak
expiratori
fl
ow
return
normal
exacerb
day
exacerb
return
baselin
lung
function
recoveri
longer
presenc
increas
dyspnoea
symptom
common
cold
exacerb
th
e
chang
observ
lung
function
exacerb
smaller
observ
asthmat
exacerb
though
averag
durat
asthmat
exacerb
longer
day
th
e
reason
incomplet
recoveri
symptom
lung
function
clear
may
involv
inadequ
treatment
persist
caus
agent
th
e
incomplet
physiolog
recoveri
exacerb
could
contribut
declin
lung
function
time
patient
copd
howev
date
evid
patient
incomplet
recoveri
exacerb
greater
declin
lung
function
studi
natur
histori
copd
exacerb
requir
recent
audit
perform
royal
colleg
physician
london
show
patient
seen
hospit
index
exacerb
seen
possibl
readmit
recurr
exacerb
within
week
cohort
moderatetosever
copd
patient
patient
recurr
exacerb
within
day
fi
rst
index
exacerb
event
separ
discret
index
exacerb
th
us
exacerb
complex
event
care
followup
essenti
ensur
complet
recoveri
th
e
associ
symptom
increas
dyspnoea
common
cold
exacerb
prolong
recoveri
suggest
viral
infect
may
lead
prolong
exacerb
cold
associ
longer
exacerb
copd
patient
develop
cold
may
prone
sever
exacerb
consid
therapi
earli
onset
symptom
copd
exacerb
also
prone
recurr
one
exacerb
like
follow
anoth
one
copd
exacerb
associ
rise
airway
upper
lower
airway
system
infl
ammat
increas
system
marker
seen
exacerb
like
driven
increas
airway
infl
ammat
exacerb
chang
airway
system
infl
ammat
exacerb
directli
relat
obvious
biopsi
studi
diffi
cult
perform
exacerb
copd
patient
howev
one
studi
biopsi
perform
exacerb
patient
chronic
bronchiti
increas
airway
eosinophilia
found
though
patient
studi
mild
copd
exacerb
modest
increas
observ
neutrophil
tlymphocyt
cell
ozon
studi
acut
infect
exacerb
chronic
bronchiti
found
one
factor
predict
exacerb
also
number
previou
year
though
studi
limit
exacerb
present
purul
sputum
physiolog
data
avail
studi
prospect
analysi
exacerb
daili
monitor
perform
deterior
symptom
though
signifi
cant
peak
expiratori
fl
ow
chang
fall
peak
expiratori
fl
ow
fev
exacerb
gener
small
use
predict
exacerb
larger
fall
peak
expiratori
fl
ow
associ
symptom
dyspnoea
presenc
greater
airway
inflamm
chang
tcell
macrophag
mast
cell
qiu
cowork
studi
biopsi
copd
patient
intub
show
consider
airway
neutrophilia
neutrophil
elastas
express
upregul
neutrophil
chemokin
express
howev
intub
copd
patient
may
secondari
airway
infect
thu
result
may
diffi
cult
interpret
oxid
stress
also
play
import
role
develop
airway
infl
ammat
copd
exacerb
marker
oxid
stress
shown
rise
airway
exacerb
hydrogen
peroxid
marker
may
take
time
recov
baselin
stabl
level
patient
sever
exacerb
associ
hospitalizationassist
ventil
show
evid
increas
oxid
stress
studi
airway
infl
ammatori
marker
exacerb
perform
use
sputum
sampl
either
spontan
induc
sputum
infl
ammatori
marker
myeloperoxidas
mpo
rise
start
exacerb
usual
recov
normal
day
though
case
higher
airway
infl
ammatori
marker
may
persist
time
suggest
incomplet
recoveri
exacerb
perera
colleagu
also
show
system
infl
ammat
may
persist
exacerb
patient
elev
creactiv
protein
crp
week
onset
exacerb
like
develop
earli
recurr
exacerb
patient
histori
frequent
exacerb
also
increas
airway
system
infl
ammat
stabl
state
compar
patient
infrequ
exacerb
copd
exacerb
associ
number
aetiolog
factor
includ
infect
pollut
episod
tabl
copd
exacerb
frequent
trigger
upper
respiratori
tract
infect
common
winter
month
respiratori
viral
infect
commun
patient
may
also
prone
exacerb
winter
month
lung
function
copd
patient
show
small
signifi
cant
fall
reduct
outdoor
temperatur
winter
month
copd
patient
found
increas
hospit
admiss
suggest
increas
exacerb
increas
environment
pollut
occur
decemb
pollut
episod
uk
copd
mortal
increas
togeth
increas
hospit
admiss
elderli
copd
patient
howev
common
pollut
especi
oxid
nitrogen
particul
may
interact
viral
infect
precipit
exacerb
rather
act
alon
viral
infect
import
trigger
copd
exacerb
studi
shown
least
onethird
copd
exacerb
associ
viral
infect
major
due
human
rhinoviru
caus
common
cold
viral
exacerb
associ
symptomat
cold
prolong
recoveri
exacerb
use
molecular
techniqu
seemung
colleagu
also
show
rhinoviru
recov
induc
sputum
frequent
nasal
aspir
exacerb
suggest
wildtyp
rhinoviru
infect
lower
airway
contribut
infl
ammatori
chang
exacerb
th
ey
also
found
exacerb
associ
presenc
rhinoviru
induc
sputum
larger
increas
airway
level
suggest
virus
increas
sever
airway
infl
ammat
exacerb
th
fi
nding
agreement
data
respiratori
virus
produc
longer
sever
exacerb
major
impact
health
care
util
virus
may
trigger
copd
exacerb
though
coronaviru
associ
small
proport
asthmat
exacerb
unlik
play
major
role
copd
rsv
respiratori
syncyti
viru
infl
uenza
parainfl
uenza
adenoviru
trigger
exacerb
infl
uenza
becom
less
promin
caus
exacerb
introduct
immun
though
still
like
import
factor
time
infl
uenza
epidem
rsv
infect
found
copd
exacerb
clear
rsv
caus
copd
exacerb
rsv
frequent
detect
airway
copd
patient
stabl
past
year
role
bacteri
infect
copd
exacerb
somewhat
controversi
airway
bacteri
colon
found
patient
stabl
state
organ
isol
exacerb
th
ese
includ
haemophilu
infl
uenza
streptococcu
pneumonia
branhamella
cattarhali
staphylococcu
aureu
pseudomona
aeruginosa
studi
patient
moderatetosever
copd
bacteria
found
patient
stabl
state
exacerb
bacteri
detect
rose
associ
rise
airway
bacteri
load
th
e
case
involv
bacteria
come
studi
antibiot
therapi
exacerb
often
present
increas
sputum
purul
volum
antibiot
tradit
use
fi
rstline
therapi
exacerb
anthonisen
colleagu
classic
paper
investig
benefi
antibiot
acut
exacerb
demonstr
greater
treatment
success
rate
patient
treat
antibiot
especi
initi
present
symptom
increas
dyspnoea
sputum
volum
purul
patient
mild
copd
obtain
less
benefi
antibiot
therapi
metaanalysi
trial
antibiot
therapi
copd
conclud
antibiot
therapi
ere
small
signifi
cant
benefi
outcom
exacerb
sethi
colleagu
suggest
isol
new
bacteri
strain
copd
patient
regularli
sampl
associ
increas
risk
exacerb
though
also
conclus
prove
bacteria
direct
caus
exacerb
exacerb
associ
strain
chang
strain
chang
result
exacerb
copd
exacerb
respiratori
virus
bacteria
may
isol
greater
system
infl
ammatori
respons
report
exacerb
associ
h
infl
uenza
rhinoviru
isol
isol
haemophilu
associ
new
worsen
coryz
symptom
surrog
viral
infect
infect
sever
assess
chang
symptom
lung
function
exacerb
onset
th
confi
rmed
studi
demonstr
greater
lung
function
impair
longer
hospitalizaton
exacerb
associ
viral
bacteri
coinfect
also
suggest
atyp
microorgan
chlamydia
mycoplasma
may
caus
copd
exacerb
though
evid
role
confl
ict
infect
agent
may
interact
bacteria
virus
airway
patient
moder
sever
copd
mechan
perform
respiratori
muscl
reduc
th
e
airfl
ow
obstruct
lead
hyperinfl
ation
respiratori
muscl
act
mechan
disadvantag
gener
reduc
inspiratori
pressur
th
e
load
respiratori
muscl
also
increas
patient
airfl
ow
obstruct
presenc
intrins
posit
endexpiratori
pressur
peep
exacerb
copd
increas
airfl
ow
obstruct
increas
load
respiratori
muscl
increas
work
breath
precipit
respiratori
failur
sever
case
th
e
minut
ventil
may
normal
respiratori
pattern
irregular
increas
frequenc
decreas
tidal
volum
th
e
result
hypercapnia
acidosi
reduc
inspiratori
muscl
function
contribut
deterior
respiratori
failur
hypoxaemia
copd
usual
occur
due
combin
ventilationperfus
mismatch
hypoventil
although
arterioven
shunt
also
contribut
acut
set
th
caus
increas
pulmonari
arteri
pressur
lead
salt
water
retent
develop
edema
th
e
degre
ventil
perfus
abnorm
increas
acut
exacerb
resolv
follow
week
acidosi
import
prognost
factor
surviv
respiratori
failur
copd
exacerb
thu
earli
correct
acidosi
essenti
goal
therapi
beta
agonist
anticholinerg
agent
inhal
bronchodil
frequent
use
treatment
acut
exacerb
copd
patient
stabl
copd
symptomat
benefi
obtain
bronchodil
therapi
copd
even
without
signifi
cant
chang
spirometri
th
probabl
due
reduct
dynam
hyperinfl
ation
characterist
copd
henc
lead
decreas
sensat
dyspnoea
especi
exert
stabl
copd
greater
bronchodilat
demonstr
anticholinerg
agent
agonist
may
due
excess
cholinerg
neuron
bronchoconstrictor
tone
howev
studi
investig
bronchodil
respons
acut
exacerb
copd
shown
diff
erenc
agent
use
signifi
cant
addit
eff
ect
combin
therapi
even
though
combin
anticholinerg
bronchodil
benefi
ts
stabl
state
th
diff
erenc
eff
ect
acut
stabl
state
may
due
fact
larger
dose
drug
deliv
acut
set
produc
maxim
bronchodilat
wherea
smaller
dose
administ
stabl
condit
may
submaxim
eff
ect
methylxanthin
theophyllin
sometim
use
manag
acut
exacerb
copd
th
ere
evid
theophyllin
use
copd
though
main
limit
factor
frequenc
toxic
side
eff
ect
th
e
therapeut
action
theophyllin
thought
due
inhibit
phosphodiesteras
break
cyclic
adenosin
monophosph
amp
intracellular
messeng
thu
facilit
bronchodilat
howev
studi
intraven
aminophyllin
therapi
acut
exacerb
copd
shown
signifi
cant
benefi
cial
eff
ect
convent
therapi
th
ere
report
benefi
cial
eff
ect
methylxanthin
upon
diaphragmat
cardiac
function
though
mechan
requir
studi
patient
copd
exacerb
patient
stabl
copd
show
spirometr
respons
oral
corticosteroid
unlik
situat
asthma
steroid
littl
eff
ect
airway
infl
ammatori
marker
patient
copd
number
earli
studi
investig
eff
ect
corticosteroid
therapi
copd
exacerb
earli
control
trial
patient
copd
exacerb
acut
respiratori
failur
albert
cowork
found
larger
improv
preand
postbronchodil
fev
patient
treat
fi
rst
day
hospit
admiss
intraven
methylprednislon
treat
placebo
anoth
trial
found
singl
dose
methylprednisolon
given
within
min
arriv
accid
emerg
depart
produc
improv
h
spirometri
also
eff
ect
hospit
admiss
though
anoth
studi
reduc
readmiss
retrospect
studi
compar
patient
treat
steroid
exacerb
compar
treat
show
steroid
group
reduc
chanc
relaps
therapi
th
ompson
colleagu
gave
day
cours
prednisolon
placebo
random
manner
outpati
present
acut
exacerb
copd
unlik
previou
studi
patient
either
recruit
outpati
group
preenrol
self
report
exacerb
studi
team
studi
patient
exacerb
associ
acidosi
pneumonia
exclud
exacerb
moder
sever
gener
includ
patient
steroidtr
group
show
rapid
improv
pao
alveolararteri
oxygen
gradient
fev
peak
expiratori
fl
ow
rate
trend
toward
rapid
improv
dyspnoea
steroidtr
group
recent
cohort
studi
seemung
colleagu
eff
ect
therapi
prednisolon
copd
exacerb
diagnos
treat
commun
studi
exacerb
treat
steroid
sever
associ
larger
fall
peak
expiratori
fl
ow
th
e
treat
exacerb
also
longer
recoveri
time
baselin
symptom
peak
expiratori
fl
ow
howev
rate
peak
expiratori
fl
ow
recoveri
faster
prednisolonetr
group
though
rate
symptom
score
recoveri
interest
fi
nding
studi
steroid
signifi
cantli
prolong
median
time
day
onset
initi
exacerb
next
exacerb
day
group
treat
prednisolon
day
patient
treat
prednisolon
contrast
antibiot
therapi
eff
ect
time
next
exacerb
short
cours
oral
steroid
therapi
exacerb
prolong
time
next
exacerb
could
import
way
reduc
exacerb
frequenc
copd
patient
import
determin
health
statu
davi
colleagu
random
patient
admit
hospit
copd
exacerb
prednisolon
placebo
prednisolon
group
fev
rose
faster
day
plateau
observ
steroidtr
group
chang
prebronchodil
postbronchodil
fev
similar
suggest
eff
ect
bronchomotor
tone
involv
faster
resolut
airway
infl
ammatori
chang
airway
wall
edema
exacerb
length
hospit
stay
analysi
show
patient
treat
prednisolon
signifi
cantli
shorter
length
stay
six
week
later
diff
erenc
spirometri
patient
group
health
statu
similar
measur
day
admiss
th
us
benefi
ts
steroid
therapi
exacerb
obviou
earli
cours
exacerb
similar
proport
patient
studi
group
requir
treatment
exacerb
within
week
followup
emphas
high
exacerb
frequenc
patient
niewoehn
colleagu
perform
random
control
trial
either
prednisolon
cours
exacerb
compar
placebo
addit
exacerb
therapi
th
e
primari
end
point
fi
rst
treatment
failur
includ
death
need
intub
readmiss
intensifi
cation
therapi
th
ere
diff
erenc
result
use
week
treatment
protocol
th
e
rate
treatment
failur
higher
placebo
group
day
compar
combin
week
prednislon
group
studi
davi
colleagu
fev
improv
faster
prednisolonetr
group
though
diff
erenc
week
contrast
niewoehn
colleagu
perform
detail
evalu
steroid
complic
found
consider
evid
hyperglycaemia
steroidtr
patient
th
us
steroid
use
copd
exacerb
short
cours
week
durat
avoid
risk
complic
acut
exacerb
copd
often
present
increas
sputum
purul
volum
antibiot
tradit
use
fi
rstline
therapi
exacerb
howev
viral
infect
may
trigger
signifi
cant
proport
acut
infect
exacerb
copd
antibiot
use
consequ
secondari
infect
discuss
previous
antibiot
therapi
exacerb
use
patient
present
symptom
increas
dyspnoea
sputum
volum
purul
random
placebocontrol
studi
investig
valu
antibiot
patient
mild
obstruct
lung
diseas
commun
conclud
antibiot
therapi
acceler
recoveri
reduc
number
relaps
though
patient
mix
patholog
hypoxaemia
occur
sever
exacerb
usual
requir
hospit
admiss
caution
alway
taken
provid
supplement
oxygen
patient
copd
particularli
acut
exacerb
respiratori
drive
muscl
strength
impair
lead
signifi
cant
increas
carbon
dioxid
tension
rel
modest
oxygen
fl
ow
rate
howev
vast
major
case
administr
supplement
oxygen
increas
arteri
oxygen
tension
suffi
cientli
without
clinic
signific
rise
carbon
dioxid
suggest
supplement
oxygen
deliv
initi
fl
ow
rate
lmin
via
nasal
cannula
inspir
oxygen
via
venturi
mask
repeat
blood
ga
analysi
min
oxygen
therapi
hypercapnia
copd
exacerb
may
manag
initi
use
respiratori
stimul
th
e
commonli
use
doxapram
act
central
increas
respiratori
drive
respiratori
muscl
activ
th
e
eff
ect
probabl
appreci
h
main
factor
limit
use
side
eff
ect
lead
agit
often
toler
patient
th
ere
studi
clinic
effi
caci
doxapram
shortterm
investig
suggest
improv
acidosi
arteri
carbon
dioxid
tension
attain
small
studi
compar
doxapram
noninvas
ventil
nppv
acut
exacerb
copd
suggest
nppv
superior
regard
correct
blood
gase
initi
treatment
phase
increas
pulmonari
arteri
pressur
acut
exacerb
copd
result
rightsid
cardiac
dysfunct
develop
peripher
edema
diuret
therapi
may
thu
necessari
edema
rise
jugular
venou
pressur
th
e
introduct
noninvas
posit
pressur
ventil
nppv
use
nasal
face
mask
major
impact
manag
acut
exacerb
enabl
acidosi
correct
earli
stage
studi
shown
nippv
produc
improv
ph
rel
rapidli
h
institut
ventil
th
allow
time
convent
therapi
work
oxygen
therapi
bronchodil
steroid
antibiot
thu
revers
progress
respiratori
failur
reduc
mortal
nippv
improv
minut
ventil
reduct
respiratori
rate
transdiaphragmat
activ
th
us
nippv
improv
ga
exchang
allow
respiratori
muscl
rest
respiratori
failur
use
nippv
patient
comfort
improv
also
requir
sedat
preserv
speech
swallow
th
e
techniqu
appli
gener
ward
though
highdepend
area
prefer
intens
care
unnecessari
patient
cooper
import
applic
nippv
th
e
main
advantag
use
nippv
avoid
tracheal
intub
abil
er
ventilatori
support
patient
respiratori
failur
due
sever
copd
would
consid
unsuit
intub
lower
incid
nosocomi
penumonia
also
report
use
nppv
compar
convent
intub
ventil
follow
number
uncontrol
studi
random
control
trial
shown
benefi
nippv
acut
copd
exacerb
uk
studi
show
use
nippv
exacerb
respiratori
failur
earlier
correct
ph
achiev
togeth
reduct
breathless
initi
day
ventil
compar
control
standard
therapi
group
studi
unit
state
show
signifi
cant
reduct
intub
rate
nippv
group
receiv
convent
therapi
nippv
group
third
studi
show
convincingli
patient
exacerb
respiratori
failur
use
nippv
pressur
support
ventil
reduc
need
intub
mortal
signifi
cantli
reduc
convent
treat
group
nippv
group
complic
specifi
calli
associ
use
mechan
ventil
also
reduc
th
e
diff
erenc
mortal
disappear
adjust
intub
suggest
benefi
ts
nippv
due
fewer
patient
requir
intub
th
also
fi
rst
studi
show
hospit
length
stay
reduc
use
nippv
recent
studi
show
nppv
appli
gener
ward
though
patient
sever
acidosi
wors
outcom
th
ese
studi
treat
patient
ph
rather
prognosi
copd
worsen
number
patient
may
improv
without
nippv
though
seem
major
eff
ect
nippv
earlier
correct
acidosi
thu
avoid
tracheal
intub
associ
complic
studi
shown
nippv
success
implement
case
nippv
less
success
patient
wors
blood
gase
baselin
ventil
underweight
higher
incid
pneumonia
greater
level
neurolog
deterior
complianc
ventil
poor
moretti
colleagu
recent
shown
late
treatment
failur
initi
h
therapi
nppv
patient
late
failur
like
sever
function
clinic
diseas
complic
time
admiss
identifi
cation
patient
potenti
poor
outcom
import
delay
intub
seriou
consequ
patient
nippv
fail
unavail
hospit
invas
ventil
may
requir
presenc
increas
acidosi
may
consid
patient
ph
fall
decis
ventil
patient
may
diffi
cult
though
improv
mode
invas
ventilatori
support
better
wean
techniqu
outlook
copd
patient
better
patient
suitabl
tracheal
intub
fi
rst
present
copd
exacerb
respiratori
failur
treatabl
caus
respiratori
failur
pneumonia
inform
requir
histori
qualiti
life
especi
abil
perform
daili
activ
patient
sever
disabl
progress
copd
may
less
suitabl
import
adequ
appropri
therapi
use
patient
document
diseas
progress
th
e
patient
wish
close
rel
consid
decis
institut
withhold
life
support
therapi
mani
hospit
admiss
relat
exacerb
copd
thu
reduct
admiss
especi
winter
month
frequent
particularli
desir
last
year
number
diff
erent
model
support
discharg
develop
evalu
patient
discharg
earli
appropri
packag
care
organ
includ
domiciliari
visit
made
patient
discharg
train
respiratori
nurs
cotton
colleagu
random
patient
discharg
next
day
usual
manag
found
diff
erenc
mortal
readmiss
rate
two
group
th
ere
reduct
hospit
stay
mean
day
day
anoth
larger
studi
skwarska
colleagu
patient
random
discharg
day
assess
convent
manag
diff
erenc
readmiss
rate
diff
erenc
visit
primari
care
physician
health
statu
measur
week
discharg
similar
two
group
th
e
author
also
demonstr
signifi
cant
cost
save
around
home
support
group
compar
admit
group
howev
consider
need
taken
account
organ
assist
discharg
servic
resourc
releas
nurs
follow
patient
benefi
ts
may
season
copd
admiss
particular
problem
winter
work
requir
diff
erent
model
support
discharg
avail
cost
eff
ectiv
programm
th
ere
much
recent
emphasi
prevent
exacerb
patient
copd
respiratori
tract
infect
common
factor
caus
exacerb
infl
uenza
pneumococc
vaccin
recommend
patient
signifi
cant
copd
studi
review
outcom
infl
uenza
vaccin
cohort
elderli
patient
chronic
lung
diseas
found
infl
uenza
vaccinaiton
associ
signifi
cant
health
benefi
ts
fewer
outpati
visit
fewer
hospit
reduc
mortal
longterm
antibiot
therapi
use
past
patient
frequent
exacerb
though
evid
strong
benefi
howev
advent
novel
specifi
c
antibiot
airway
organ
topic
longterm
antibiot
therapi
copd
current
revisit
result
fi
rst
trial
await
recent
report
eff
ect
immunostimulatori
agent
patient
copd
exacerb
reduct
sever
complic
hospit
admiss
activ
treat
group
howev
mechan
benefi
clear
studi
eff
ect
agent
prevent
copd
exacerb
requir
longact
bronchodil
laba
shown
reduc
exacerb
recent
report
torch
toward
revolut
copd
health
studi
salmeterol
longact
beta
agonist
reduc
frequenc
exacerb
number
studi
shown
longact
anticholinerg
tiotropium
reduc
exacerb
rate
also
trend
reduct
hospit
admiss
howev
good
evid
present
longact
anticholinerg
agent
possess
antiinfl
ammatori
activ
like
tiotropium
reduc
exacerb
reduc
dynam
hyperinfl
ation
thu
dyspnoea
combin
longact
beta
agonist
inhal
corticosteroid
also
evalu
reduc
exacerb
individu
compon
direct
comparison
inhal
tiotropium
salmeterolfl
uticason
sfc
combin
recent
report
inspir
studi
moderatetosever
copd
patient
show
intervent
equal
eff
ect
exacerb
rate
howev
patient
take
tiotropium
requir
cours
oral
corticosteroid
exacerb
wherea
patient
sfc
combin
requir
cours
antibiot
th
fi
rst
time
shown
differ
intervent
diff
erent
eff
ect
exacerb
th
e
optim
studi
recent
evalu
combin
tiotropium
inhal
laba
salmeterol
inhal
steroid
fl
luticason
th
e
tripl
combin
reduc
hospit
result
exacerb
total
number
exacerb
addit
trend
observ
reduct
number
exacerb
tripl
combin
reach
statist
signifi
canc
due
rel
small
size
studi
high
dropout
rate
tripl
therapi
may
eff
ectiv
therapi
studi
combin
requir
adequ
power
studi
